A 2026 Australian interview study involving 27 adults with methamphetamine use problems found that 21 participants, or 77.8%, had never previously sought treatment for methamphetamine use. Research Highlights Most had never sought treatment: Peart et al. interviewed 27 adults and found that 77.8% had not previously sought methamphetamine treatment before entering the parent trial.1 3 …
A 12-week randomized pilot trial in 60 Veterans with depression and psychiatric polypharmacy found that 30% had an actionable antidepressant gene-drug interaction, but immediate access to pharmacogenomic results did not clearly change prescribing or Patient Health Questionnaire-9 depression scores compared with delayed access.1 Research Highlights Actionable PGx results were common: 18 of 60 Veterans, or …
A 2026 nationwide Korean analysis found that resistance exercise was associated with lower depression and anxiety scores after propensity score matching, while aerobic exercise alone was not significantly associated with either outcome. The result favors adding weights, bands, machines, or body-weight strength work to mental-health exercise advice without assuming that lifting caused the lower symptom …
A 2026 qualitative analysis treated suicide-themed sculpture as cultural evidence, showing how public artworks can materialize psychological pain, shame, entrapment, social disconnection, and prevention debates without turning artists or viewers into diagnostic case studies.1 Research Highlights 2026 analysis used cultural methods: the researchers used iconographic, semiotic, and contextual analysis rather than clinical diagnosis or outcome …
A 2026 multimodal MRI study found that treatment-resistant depression had lower coordination between brain structure and brain activity than non-treatment-resistant depression in frontal, parietal, motor, and temporal regions. Machine-learning models using those structure-function coupling measures classified treatment-resistant vs. non-treatment-resistant depression with AUC values from 0.886 to 0.950 in the primary atlas analysis.1 Research Highlights TRD …
The endogenous opioid system has been a candidate target for novel anxiety treatments, but a 2026 placebo-controlled crossover fMRI study in 38 healthy volunteers ran opposite the hypothesis: instead of increasing threat-related distress and amygdala reactivity, 50 mg oral naltrexone reduced subjective distress during cognitive reappraisal (p = 0.044, d = 0.57) and shifted ventromedial …
Intranasal esketamine — FDA-approved for treatment-resistant depression in 2019 — failed cost-effectiveness benchmarks against four cheaper third-line options in a 2026 Hong Kong modeling study, with incremental cost-effectiveness ratios (ICERs) of US$134,127 to US$312,750 per quality-adjusted life-year (QALY) at a US$50,000/QALY willingness-to-pay (WTP) threshold.1 Combination antidepressant therapy was the most cost-effective strategy modeled. Research Highlights …